Get the Stockscreener App
1.23
1.60%
-0.02
After Hours:
1.21
-0.02
-1.63%
Quince Therapeutics Inc stock is traded at $1.23, with a volume of 2.49M.
It is down -1.60% in the last 24 hours and up +15.49% over the past month.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
See More
Previous Close:
$1.25
Open:
$1.17
24h Volume:
2.49M
Relative Volume:
0.27
Market Cap:
$20.05M
Revenue:
-
Net Income/Loss:
$-83.98M
P/E Ratio:
-0.0921
EPS:
-13.3519
Net Cash Flow:
$-41.78M
1W Performance:
-32.82%
1M Performance:
+15.49%
6M Performance:
-93.79%
1Y Performance:
-87.82%
1-Day Range:
$1.12
$1.25
1-Week Range:
$1.12
$1.589
52-Week Range:
$0.80
$45.50
Quince Therapeutics Inc Stock (QNCX) Company Profile
Name
Quince Therapeutics Inc
Sector
Industry
Phone
415-910-5717
Address
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
Compare QNCX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QNCX
Quince Therapeutics Inc
|
1.23 | 20.38M | 0 | -83.98M | -41.78M | -13.35 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Quince Therapeutics Inc Stock (QNCX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Aug-05-25 | Initiated | Citizens JMP | Mkt Outperform |
| Mar-24-25 | Initiated | Oppenheimer | Outperform |
Quince Therapeutics Inc Stock (QNCX) Latest News
Why is QNCX stock up 60% pre-market after a near-total wipeout? - MSN
Earnings Beat: Should I hold or sell Quince Therapeutics Inc now2026 Growth vs Value & Consistent Profit Trade Alerts - baoquankhu1.vn
Treasury Yields: Whats Quince Therapeutics Incs historical returnMarket Trend Report & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Aug Opening: Can Quince Therapeutics Inc sustain its profitabilityM&A Rumor & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
symbol__ Stock Quote Price and Forecast - CNN
Quince Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView — Track All Markets
QNCX: Lead asset failed in Phase 3, triggering strategic review and raising going concern risks - TradingView — Track All Markets
Phase 3 miss leaves Quince Therapeutics (QNCX) chasing reverse merger path - Stock Titan
Quince Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Quince Therapeutics Announces 1-for-10 Reverse Stock Split - The Globe and Mail
Quince Therapeutics To Carry Out 1-for-10 Reverse Stock Split On April 13th, 2026 - Moomoo
Quince Therapeutics to implement 1-for-10 reverse stock split effective Friday - Investing.com Australia
Quince Therapeutics, Inc. Files Form 8-K Announcing Certificate of Amendment and Company Details - Minichart
Quince Therapeutics to implement 1-for-10 reverse stock split effective Friday By Investing.com - Investing.com South Africa
Form 8-KCurrent report - ADVFN
Dow Jumps Over 1,300 Points; Delta Air Lines Shares Gain After Q1 Results - Sahm
12 Health Care Stocks Moving In Tuesday's After-Market Session - Sahm
9 Health Care Stocks Moving In Wednesday's Pre-Market Session - Sahm
History Review: Is Quince Therapeutics Inc stock overvalued or fairly pricedEarnings Recap Summary & Weekly Setup with ROI Potential - baoquankhu1.vn
$Quince Therapeutics (QNCX.US)$ thanks 🤑🤑🤑 - Moomoo
$Quince Therapeutics (QNCX.US)$ goodluck guy - Moomoo
$Quince Therapeutics (QNCX.US)$ mon stop fight it - Moomoo
$Quince Therapeutics (QNCX.US)$ thank clear - Moomoo
$Quince Therapeutics (QNCX.US)$ awwww - Moomoo
$Quince Therapeutics (QNCX.US)$ i just sold off my initial investment - Moomoo
Plays for 4-08-2026 $BTC Digital (BTCT.US)$ $Quince Therapeutics (QNCX.US)$ - Moomoo
still holding - Moomoo
Trending Stocks Today | U Power Surges 59.06% Post-Market - Moomoo
$Quince Therapeutics (QNCX.US)$ good quience..good - Moomoo
QNCX PE Ratio & Valuation, Is QNCX Overvalued - Intellectia AI
Quince Therapeutics Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView — Track All Markets
Quince Therapeutics settles $16.4M debt with $5.5M payment - MSN
QNCX Stock Price, Quote & Chart | QUINCE THERAPEUTICS INC (NASDAQ:QNCX) - ChartMill
Quince Therapeutics Delays Annual 10-K Filing - TipRanks
Quince Therapeutics (QNCX) delays 2025 10-K after failed Phase 3; seeks 15-day extension - Stock Titan
QNCX Stock News Today | Earnings, Events & Price Alerts - intellectia.ai
Aug Setups: Will Quince Therapeutics Inc benefit from AI trends2026 Earnings & Fast Moving Trade Plans - baoquankhu1.vn
Quince Therapeutics settles $16.4M debt for $5.5M payment By Investing.com - Investing.com South Africa
Quince Therapeutics (QNCX) Resolves Debt with European Investmen - GuruFocus
Quince Therapeutics Settles $16.4 Million in Debt - National Today
Curious about the most active stocks on Monday? - ChartMill
Quince Therapeutics settles EIB loan obligations for $5.5 mln - marketscreener.com
Quince Therapeutics Settles EIB Loan Obligations For $5.5 Mln - TradingView
Stocks Under $0.10: ITRM, AMLM, BFRG, QNCX, ADMQ March Madness Watch - openpr.com
Quince Therapeutics settles approximately $16.4 million of debt - marketscreener.com
Quince Therapeutics Settles $16.4 Million Debt for $5.5 Million, Advances Strategic Restructuring - minichart.com.sg
Quince Therapeutics Eliminates EIB Debt, Boosts Flexibility - TipRanks
Quince Therapeutics Settles Approximately $16.4 Million Of Debt - TradingView
Quince Therapeutics, Inc. Settles Approximately $16.4 Million of Debt - marketscreener.com
Why did QNCX stock surge 40% in pre-market today? - MSN
Quince Therapeutics settles $16.4M debt for $5.5M payment - Investing.com
Quince Therapeutics Inc Stock (QNCX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):